David C. Bibby

1.5k total citations
26 papers, 775 citations indexed

About

David C. Bibby is a scholar working on Pharmaceutical Science, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David C. Bibby has authored 26 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmaceutical Science, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David C. Bibby's work include Advanced Drug Delivery Systems (6 papers), Drug Solubulity and Delivery Systems (4 papers) and Immune Response and Inflammation (4 papers). David C. Bibby is often cited by papers focused on Advanced Drug Delivery Systems (6 papers), Drug Solubulity and Delivery Systems (4 papers) and Immune Response and Inflammation (4 papers). David C. Bibby collaborates with scholars based in United Kingdom, United States and Australia. David C. Bibby's co-authors include Nigel Davies, Ian G. Tucker, R.F. Grimble, Jean‐Pierre Benoît, Marie‐Claire Venier‐Julienne, Anne Aubert‐Pouëssel, Stephen Barry, Scott G. Kurz, Matthias Steiert and James E. Talmadge and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Physiology and Cancer Research.

In The Last Decade

David C. Bibby

25 papers receiving 756 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David C. Bibby United Kingdom 11 288 232 224 121 87 26 775
Rajendra S. Kadam United States 18 295 1.0× 167 0.7× 389 1.7× 123 1.0× 73 0.8× 27 1.2k
Eleonora Santucci Italy 20 388 1.3× 151 0.7× 328 1.5× 95 0.8× 139 1.6× 51 1.1k
Jacques‐Emile Proust France 8 320 1.1× 236 1.0× 376 1.7× 95 0.8× 120 1.4× 9 797
M.R. Aberturas Spain 17 477 1.7× 329 1.4× 271 1.2× 123 1.0× 114 1.3× 25 1.1k
Ankur Kaul India 19 223 0.8× 330 1.4× 335 1.5× 162 1.3× 120 1.4× 66 970
Sandip B. Tiwari United States 16 509 1.8× 247 1.1× 241 1.1× 127 1.0× 50 0.6× 20 955
Ignazio Giannone Italy 8 340 1.2× 292 1.3× 163 0.7× 143 1.2× 71 0.8× 11 661
Gopal Venkatesh Shavi India 16 329 1.1× 255 1.1× 195 0.9× 118 1.0× 43 0.5× 21 680
Yanan Shi China 20 494 1.7× 335 1.4× 378 1.7× 161 1.3× 59 0.7× 53 1.1k
Jan Barthelmes Austria 18 750 2.6× 285 1.2× 255 1.1× 73 0.6× 103 1.2× 24 1.0k

Countries citing papers authored by David C. Bibby

Since Specialization
Citations

This map shows the geographic impact of David C. Bibby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Bibby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Bibby more than expected).

Fields of papers citing papers by David C. Bibby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Bibby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Bibby. The network helps show where David C. Bibby may publish in the future.

Co-authorship network of co-authors of David C. Bibby

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Bibby. A scholar is included among the top collaborators of David C. Bibby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Bibby. David C. Bibby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Smith, David A., Daniel Bradshaw, Jean L. Mbisa, et al.. (2020). Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir. Journal of Hepatology. 73. S336–S336. 1 indexed citations
3.
Nowak, Anna K., Chris Brown, Michael Millward, et al.. (2013). A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 81(3). 422–427. 44 indexed citations
4.
Sarantopoulos, John, Long H. Dang, Richard C. Lauer, et al.. (2013). A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial.. Journal of Clinical Oncology. 31(15_suppl). 4563–4563. 1 indexed citations
5.
Hutson, Thomas E., Long H. Dang, Richard C. Lauer, et al.. (2012). Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).. Journal of Clinical Oncology. 30(5_suppl). 373–373. 2 indexed citations
6.
Lavranos, Tina C., et al.. (2012). Abstract 2774: Anti-cancer activity of the tumor-selective, hypoxia-inducing, agent BNC105 in platinum resistant ovarian cancer. Cancer Research. 72(8_Supplement). 2774–2774. 3 indexed citations
7.
Rischin, Danny, David C. Bibby, Geoff Chong, et al.. (2011). Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation. Clinical Cancer Research. 17(15). 5152–5160. 54 indexed citations
8.
Chong, Geoffrey, David C. Bibby, Gabriel Kremmidiotis, et al.. (2010). A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation.. Journal of Clinical Oncology. 28(15_suppl). 3054–3054. 2 indexed citations
9.
Kremmidiotis, Gabriel, et al.. (2009). Abstract #5564: BNC105 is a tubulin targeting agent that is not susceptible to efflux by Pgp transporter expression, and yields additive therapeutic benefit when combined with other anti-cancer agents. Cancer Research. 69. 5564–5564. 1 indexed citations
10.
Bibby, David C., James E. Talmadge, Scott G. Kurz, et al.. (2005). Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. International Journal of Pharmaceutics. 293(1-2). 281–290. 109 indexed citations
11.
Aubert‐Pouëssel, Anne, Marie‐Claire Venier‐Julienne, Anne Clavreul, et al.. (2004). In vitro study of GDNF release from biodegradable PLGA microspheres. Journal of Controlled Release. 95(3). 463–475. 96 indexed citations
12.
Bibby, David C., et al.. (2003). Encapsulation of protamine sulphate compacted DNA in polylactide and polylactide–co-glycolide microparticles. Journal of Controlled Release. 92(1-2). 209–219. 30 indexed citations
13.
Bibby, David C., et al.. (2003). Encapsulation of recombinant hepatitis B surface antigen in oligosaccharide ester derivatives by spray drying. Journal of Microencapsulation. 20(6). 759–766. 1 indexed citations
14.
Aubert‐Pouëssel, Anne, David C. Bibby, Marie‐Claire Venier‐Julienne, François Hindré, & Jean‐Pierre Benoît. (2002). A Novel in Vitro Delivery System for Assessing the Biological Integrity of Protein upon Release from PLGA Microspheres. Pharmaceutical Research. 19(7). 1046–1051. 53 indexed citations
15.
Bibby, David C., Nigel Davies, & Ian G. Tucker. (2000). Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. International Journal of Pharmaceutics. 197(1-2). 1–11. 253 indexed citations
16.
Bibby, David C., Nigel Davies, & Ian G. Tucker. (1999). Poly(acrylic acid) microspheres containing β-cyclodextrin: loading and in vitro release of two dyes. International Journal of Pharmaceutics. 187(2). 243–250. 31 indexed citations
17.
Bibby, David C., Nigel Davies, & Ian G. Tucker. (1998). Preparation and characterization of β-cyclodextrin and poly(acrylic acid) microspheres. Journal of Microencapsulation. 15(5). 629–637. 12 indexed citations
18.
Bibby, David C., William N. Charman, Susan A. Charman, Magdy N. Iskander, & Christopher J. H. Porter. (1996). Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery. International Journal of Pharmaceutics. 144(1). 61–70. 9 indexed citations
19.
Bibby, David C. & R.F. Grimble. (1990). Dietary fat modifies some metabolic actions of human recombinant tumour necrosis factor α in rats. British Journal Of Nutrition. 63(3). 653–668. 7 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajendra S. Kadam Breakdown of academic impact, for papers by Eleonora Santucci Breakdown of academic impact, for papers by Jacques‐Emile Proust Breakdown of academic impact, for papers by M.R. Aberturas Breakdown of academic impact, for papers by Ankur Kaul Breakdown of academic impact, for papers by Sandip B. Tiwari Breakdown of academic impact, for papers by Ignazio Giannone Breakdown of academic impact, for papers by Gopal Venkatesh Shavi Breakdown of academic impact, for papers by Yanan Shi Breakdown of academic impact, for papers by Jan Barthelmes
Rankless by CCL
2026